期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 8, 期 6, 页码 607-622出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2014.909724
关键词
adefovir; cost-effectiveness; drug resistance; entecavir; HBV DNA polymerase; lamivudine; roadmap approach; suboptimal responders; telbivudine; tenofovir disoproxil fumarate
There had been remarkable development in nucleos(t)ide analogues (NAs) and evolution in treatment strategies in last 15 years. Currently, there are five NAs available for chronic hepatitis B treatment, namely lamivudine, telbivudine and entecavir (nucleoside analogues), adefovir dipivoxil and tenofovir disoproxil fumarate (nucleotide analogues). The advantages of relatively infrequent side effects and easy administration per oral make NAs popular treatment options. The major drawback of earlier generation NAs is the risk of emergence of drug resistance. Current international guidelines recommend the use of more potent agents with high genetic barriers to resistance including entecavir and tenofovir as first line chronic hepatitis B treatment. However, there is no consensus regarding the subsequent treatment regimens in patients with suboptimal responses to NAs. De novo combination therapy of two NAs, response-guided therapy and roadmap concept in NAs with subsequent switch or add-on therapy can also potentially improve treatment efficacy and avoid resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据